Xenon Pharmaceuticals Inc. (XENE) and XBiotech Inc. (NASDAQ:XBIT) Comparison side by side

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and XBiotech Inc. (NASDAQ:XBIT), both competing one another are Biotechnology companies. We will contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenon Pharmaceuticals Inc. N/A 0.00 38.80M -1.52 0.00
XBiotech Inc. N/A 0.00 22.93M -0.64 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Xenon Pharmaceuticals Inc. and XBiotech Inc.

Profitability

Table 2 has Xenon Pharmaceuticals Inc. and XBiotech Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Xenon Pharmaceuticals Inc. 0.00% 0% 0%
XBiotech Inc. 0.00% -51.9% -48.9%

Volatility & Risk

Xenon Pharmaceuticals Inc. is 65.00% more volatile than Standard & Poor’s 500 because the company has a beta of 1.65. Competitively, XBiotech Inc. is 77.00% less volatile than Standard & Poor’s 500, because of the 0.23 beta.

Liquidity

The current Quick Ratio of Xenon Pharmaceuticals Inc. is 17.6 while its Current Ratio is 17.6. Meanwhile, XBiotech Inc. has a Current Ratio of 4.6 while its Quick Ratio is 4.6. Xenon Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than XBiotech Inc.

Insider and Institutional Ownership

Xenon Pharmaceuticals Inc. and XBiotech Inc. has shares held by institutional investors as follows: 75.6% and 13.5%. 1% are Xenon Pharmaceuticals Inc.’s share held by insiders. Comparatively, XBiotech Inc. has 37.8% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xenon Pharmaceuticals Inc. -2.05% -0.22% 16.97% -3.5% 51.67% 44.22%
XBiotech Inc. -1.05% 4.56% 14.22% 144.16% 114.12% 85.04%

For the past year Xenon Pharmaceuticals Inc. has weaker performance than XBiotech Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.